AMGN – Amgen Inc.
AMGN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
2.66
Margin Of Safety %
12
Put/Call OI Ratio
0.77
EPS Next Q Diff
3.4
EPS Last/This Y
8.05
EPS This/Next Y
0.9
Price
348.84
Target Price
356
Analyst Recom
2.42
Performance Q
4.43
Upside
-47.0%
Beta
0.47
Ticker: AMGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | AMGN | 387.97 | 0.83 | 0.40 | 99292 |
| 2026-03-02 | AMGN | 385.67 | 0.78 | 0.72 | 95564 |
| 2026-03-03 | AMGN | 377.17 | 0.78 | 0.56 | 98231 |
| 2026-03-04 | AMGN | 379.21 | 0.79 | 0.89 | 100015 |
| 2026-03-05 | AMGN | 367.68 | 0.79 | 0.98 | 101102 |
| 2026-03-06 | AMGN | 369.39 | 0.81 | 0.66 | 103166 |
| 2026-03-09 | AMGN | 376.97 | 0.82 | 2.29 | 100129 |
| 2026-03-10 | AMGN | 375.38 | 0.84 | 0.33 | 101985 |
| 2026-03-11 | AMGN | 377.52 | 0.82 | 2.24 | 104410 |
| 2026-03-12 | AMGN | 367.84 | 0.83 | 1.31 | 105021 |
| 2026-03-13 | AMGN | 367.79 | 0.83 | 1.31 | 105021 |
| 2026-03-17 | AMGN | 361.16 | 0.85 | 0.72 | 105653 |
| 2026-03-18 | AMGN | 351.49 | 0.81 | 1.16 | 111182 |
| 2026-03-19 | AMGN | 349.89 | 0.81 | 1.00 | 114113 |
| 2026-03-20 | AMGN | 347.56 | 0.80 | 1.22 | 114303 |
| 2026-03-23 | AMGN | 349.72 | 0.76 | 0.90 | 88179 |
| 2026-03-24 | AMGN | 348.53 | 0.79 | 1.85 | 90510 |
| 2026-03-25 | AMGN | 353.98 | 0.79 | 0.56 | 91573 |
| 2026-03-26 | AMGN | 353.76 | 0.77 | 0.89 | 94588 |
| 2026-03-27 | AMGN | 349.4 | 0.77 | 1.36 | 95648 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | AMGN | 388.14 | -1.6 | 6770.4 | 22.37 |
| 2026-03-02 | AMGN | 385.65 | -1.6 | 4264.9 | 22.37 |
| 2026-03-03 | AMGN | 377.03 | -1.6 | 4053.7 | 22.37 |
| 2026-03-04 | AMGN | 379.21 | -1.6 | 4427.4 | 22.37 |
| 2026-03-05 | AMGN | 367.58 | -1.6 | 3944.9 | 22.37 |
| 2026-03-06 | AMGN | 369.41 | -1.6 | 4415.9 | 22.37 |
| 2026-03-09 | AMGN | 376.83 | -2.0 | 4609.2 | 22.37 |
| 2026-03-10 | AMGN | 375.64 | -2.0 | 4304.0 | 22.37 |
| 2026-03-11 | AMGN | 377.58 | -2.0 | 4425.5 | 22.37 |
| 2026-03-12 | AMGN | 367.80 | -2.0 | 4007.8 | 22.37 |
| 2026-03-13 | AMGN | 366.31 | -2.0 | 4297.7 | 22.37 |
| 2026-03-17 | AMGN | 361.16 | -2.0 | 4168.6 | 22.38 |
| 2026-03-18 | AMGN | 351.45 | -2.0 | 4000.8 | 22.38 |
| 2026-03-19 | AMGN | 349.99 | -2.0 | 2587.4 | 22.38 |
| 2026-03-20 | AMGN | 347.80 | -2.0 | 2569.0 | 22.39 |
| 2026-03-23 | AMGN | 349.87 | -2.0 | 2705.2 | 22.39 |
| 2026-03-24 | AMGN | 348.58 | -2.5 | 2596.9 | 22.38 |
| 2026-03-25 | AMGN | 353.95 | -2.9 | 2819.7 | 22.38 |
| 2026-03-26 | AMGN | 353.20 | -2.9 | 2621.1 | 22.38 |
| 2026-03-27 | AMGN | 348.84 | -2.9 | 2503.0 | 22.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | AMGN | -1.09 | 0.94 | 2.68 |
| 2026-03-02 | AMGN | -1.09 | 1.34 | 2.68 |
| 2026-03-03 | AMGN | -5.83 | 1.34 | 2.68 |
| 2026-03-04 | AMGN | -5.83 | 1.34 | 2.68 |
| 2026-03-05 | AMGN | -5.83 | 1.34 | 2.68 |
| 2026-03-06 | AMGN | -5.83 | 1.34 | 2.68 |
| 2026-03-09 | AMGN | -5.83 | 1.32 | 2.68 |
| 2026-03-10 | AMGN | -5.83 | 1.32 | 2.68 |
| 2026-03-11 | AMGN | -5.83 | 1.32 | 2.81 |
| 2026-03-12 | AMGN | -5.83 | 1.32 | 2.81 |
| 2026-03-13 | AMGN | -5.83 | 1.32 | 2.81 |
| 2026-03-17 | AMGN | -5.83 | 1.40 | 2.81 |
| 2026-03-18 | AMGN | -5.83 | 1.40 | 2.81 |
| 2026-03-19 | AMGN | -5.83 | 1.40 | 2.81 |
| 2026-03-20 | AMGN | -5.83 | 1.40 | 2.81 |
| 2026-03-23 | AMGN | -5.83 | 1.42 | 2.81 |
| 2026-03-24 | AMGN | -5.83 | 1.42 | 2.81 |
| 2026-03-25 | AMGN | -5.83 | 1.42 | 2.66 |
| 2026-03-26 | AMGN | -5.83 | 1.42 | 2.66 |
| 2026-03-27 | AMGN | -5.83 | 1.42 | 2.66 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.45
Avg. EPS Est. Current Quarter
4.76
Avg. EPS Est. Next Quarter
5.85
Insider Transactions
-5.83
Institutional Transactions
1.42
Beta
0.47
Average Sales Estimate Current Quarter
8590
Average Sales Estimate Next Quarter
9496
Fair Value
392.28
Quality Score
87
Growth Score
90
Sentiment Score
79
Actual DrawDown %
10.8
Max Drawdown 5-Year %
-24.9
Target Price
356
P/E
24.5
Forward P/E
14.94
PEG
4.26
P/S
5.12
P/B
21.7
P/Free Cash Flow
23.21
EPS
14.23
Average EPS Est. Cur. Y
22.38
EPS Next Y. (Est.)
23.28
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
20.99
Relative Volume
0.82
Return on Equity vs Sector %
61.7
Return on Equity vs Industry %
52.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
2503
◆
AMGN
Healthcare
$348.77
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
38.7
Range 1M
10.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
2.6%
EPS NY
4.2%
52W%
68.1%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-2.4% upside
Upside
-2.4%
Quality
87
MoS
12%
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 31500
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN
Latest News
—
Caricamento notizie per AMGN…
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading